Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.
Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study collects the data of patients with early stage (stage I-II, N0) non-small cell lung cancer who underwent CT-guided radioactive Iodine-125 seed implantation from 2010 to 2018. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early Stage Lung Cancer | The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CT-guided Radioactive I-125 Seeds Implantation | Radiation | The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. |
| Measure | Description | Time Frame |
|---|---|---|
| Local control time | The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation. | Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019. |
| Overall survival time | The time from the date of seeds implantation to the date of death from any cause or the date of last observation. | Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events | The adverse events were evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event was measured. | Outcomes were followed up every 3 months after seeds implantation. The last follow-up timepoint is February 2019. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018 were included in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Junjie Wang, M.D. Ph.D. | Department of Radiation Oncology, Peking University Third Hospital | Principal Investigator |
Not provided
De-identified individual participant data for all primary and secondary outcome measures will be made available.
Data will be available within 6 months of the study completion.
Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |